• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    1/10/23 8:05:58 AM ET
    $APGN
    $BIOL
    $CALA
    $GMVD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • Prenetics Global (NASDAQ:PRE) stock rose 74.7% to $3.25 during Tuesday's pre-market session. The market value of their outstanding shares is at $386.2 million.
    • VYNE Therapeutics (NASDAQ:VYNE) shares increased by 69.89% to $0.33. The market value of their outstanding shares is at $18.9 million.
    • Sotera Health (NASDAQ:SHC) shares rose 66.66% to $14.4. The company's market cap stands at $4.0 billion.
    • Oak Street Health (NYSE:OSH) stock rose 36.28% to $30.76. The market value of their outstanding shares is at $7.4 billion.
    • Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 27.04% to $2.02. The company's market cap stands at $74.8 million.
    • Revelation Biosciences (NASDAQ:REVBU) shares rose 25.0% to $0.3.

    Losers

    • Biolase (NASDAQ:BIOL) stock declined by 42.2% to $0.4 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
    • G Medical Innovations (NASDAQ:GMVD) shares fell 19.32% to $3.55. The company's market cap stands at $3.5 million.
    • Calithera Biosciences (NASDAQ:CALA) shares decreased by 16.7% to $0.55. The market value of their outstanding shares is at $2.6 million.
    • Illumina (NASDAQ:ILMN) stock declined by 14.72% to $176.8. The company's market cap stands at $27.8 billion.
    • Apexigen (NASDAQ:APGN) shares declined by 13.89% to $1.55. The company's market cap stands at $34.9 million.
    • vTv Therapeutics (NASDAQ:VTVT) shares decreased by 10.92% to $0.71. The company's market cap stands at $57.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $BIOL
    $CALA
    $GMVD

    CompanyDatePrice TargetRatingAnalyst
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    Sotera Health Company
    $SHC
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    Sotera Health Company
    $SHC
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    Sotera Health Company
    $SHC
    12/18/2025Outperform
    William Blair
    vTv Therapeutics Inc.
    $VTVT
    11/19/2025$40.00Buy
    BTIG Research
    More analyst ratings

    $APGN
    $BIOL
    $CALA
    $GMVD
    SEC Filings

    View All

    vTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    3/10/26 4:37:42 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    3/10/26 4:35:39 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by vTv Therapeutics Inc.

    10-K - vTv Therapeutics Inc. (0001641489) (Filer)

    3/10/26 4:32:49 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BIOL
    $CALA
    $GMVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Roth Capital initiated coverage on vTv Therapeutics with a new price target

    Roth Capital initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $58.00

    1/23/26 8:21:38 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BIOL
    $CALA
    $GMVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gtcr Investment Xi Llc sold $152,700,000 worth of shares (10,000,000 units at $15.27) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    3/10/26 6:10:40 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SVP, Chief Technology Officer Barnard Steven was granted 7,603 shares, increasing direct ownership by 23% to 41,335 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    3/9/26 5:06:38 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M was granted 5,849 shares, increasing direct ownership by 36% to 22,183 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    3/9/26 5:05:22 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $APGN
    $BIOL
    $CALA
    $GMVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and pro

    3/10/26 4:01:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prenetics Authorizes $40 Million Share Repurchase Program

    Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027 NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the "Board") has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Management Voted With Its Own Capital First During the week of Feb

    3/6/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

    Dataset grows to more than 312,000 whole genomes with longitudinal clinical dataGSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data  SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced two advancements in scale and depth of the Alliance for Genomic Discovery (AGD or the Alliance). With the addition of Regeneron Genetics Center® (RGC®) as the tenth member, the Alliance can expand the core dataset to 312,000 whole genomes. The Alliance also announced a new initiative: a dataset of 50,000 additional whole genomes with paired proteomic data generated using Illumina® Pro

    3/5/26 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $APGN
    $BIOL
    $CALA
    $GMVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Wiggans Thomas G bought $99,630 worth of Voting Common Stock (41,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BIOL
    $CALA
    $GMVD
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and pro

    3/10/26 4:01:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    $APGN
    $BIOL
    $CALA
    $GMVD
    Financials

    Live finance-specific insights

    View All

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date

    CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2025 before the market opens on Tuesday, February 24, 2026. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's websit

    2/17/26 7:30:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $APGN
    $BIOL
    $CALA
    $GMVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care